ESR1 and breast carcinoma: However, a major clinical challenge is that although the 5-year survival rate for invasive breast cancer is 90%, over 50% of those with non-metastatic, lymph node-positive, ER+ breast cancer at diagnosis will recur within 20 years of diagnosis [5].